---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-22-000495"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:25:37.339488+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma subsidiary files provisional patent for CAR T-cell dedifferentiation method

## Summary
- KCL Therapeutics, a wholly owned subsidiary, filed a provisional patent application with USPTO on August 9, 2022.
- Patent covers methods, means and compositions for enhancing antitumor activity of CAR T cells through dedifferentiation.
- CAR T cells are modified immune T cells that attack cancer-specific antigens; developed from bone marrow stem cells.
- Provisional application marks initial step in securing IP for this cancer treatment approach.

## SEC filing metadata
- accession: 0001607062-22-000495
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/0001607062-22-000495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000495/rgbp080922form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-22-000495
- JSON: https://secwatch.observer/filing/0001607062-22-000495.json
- Plain text: https://secwatch.observer/filing/0001607062-22-000495.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.